'Keytruda has beaten Roche’s TIGIT drug candidate at the first interim analysis of a phase 2/3 lung cancer trial, prompting the Swiss drugmaker to stop the study and consider changes to the broader program.
(...)
Roche found the survival data favored the Keytruda regimen at the first interim analysis. The assessment of progression-free survival (PFS) generated a hazard ratio of 1.27.'
#Immunotherapy #Immunology
https://www.fiercebiotech.com/biotech/roche-stops-pivotal-tigit-trial-after-keytruda-lands-knockout-blow-first-attempt
Thiago Carvalho /
npub1xa…czham
2024-07-10 07:17:31
Author Public Key
npub1xakev87fgm9edqu6f5jhszwunekjxl3dpnq4sxvm3nzu2ace8xnqyczhamPublished at
2024-07-10 07:17:31Event JSON
{
"id": "a97ab3f82ee050d9c04251aba31b1c597fa9206114c59d444c0448c69ef4ed1a",
"pubkey": "376d961fc946cb96839a4d257809dc9e6d237e2d0cc158199b8cc5c5771939a6",
"created_at": 1720595851,
"kind": 1,
"tags": [
[
"t",
"immunology"
],
[
"t",
"immunotherapy"
],
[
"proxy",
"https://qoto.org/users/cyrilpedia/statuses/112760969718626340",
"activitypub"
]
],
"content": "'Keytruda has beaten Roche’s TIGIT drug candidate at the first interim analysis of a phase 2/3 lung cancer trial, prompting the Swiss drugmaker to stop the study and consider changes to the broader program.\n(...)\nRoche found the survival data favored the Keytruda regimen at the first interim analysis. The assessment of progression-free survival (PFS) generated a hazard ratio of 1.27.'\n#Immunotherapy #Immunology\nhttps://www.fiercebiotech.com/biotech/roche-stops-pivotal-tigit-trial-after-keytruda-lands-knockout-blow-first-attempt",
"sig": "8bb758ae72013fdf0a380da6da1c3b57b8baa15f501761eab861973b9ec78395d7aa43fc7955fcd2b30cb09e8008b237e9bd4edc02aa23a1bc246d5d18eebfb5"
}